Myelodysplasia and autoimmunity
- 1 January 2012
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Rheumatology
- Vol. 24 (1), 97-102
- https://doi.org/10.1097/bor.0b013e32834db4ee
Abstract
Primary myelodysplastic syndromes (MDS) are heterogeneous clonal haemopoietic stem-cell disorders clinically presented with a varying degree of peripheral cytopenias and an increased probability of leukemic evolution. The natural history of MDS ranges from more indolent forms of disease spanning years to those rapidly progressing to overt leukemia. A distinct subset of MDS patients manifest overt autoimmune manifestations (AIMs), the pathogenesis and prognostic significance of which remain controversial. This review will briefly highlight aspects of immune-mediated myelosuppression and cytokine-induced cytopenias in MDS and further analyze MDS-associated AIMs clinically and pathogenetically. Facts provided by advanced studies suggest that an immune reaction against the evolving clone, operated by macrophages, T, natural killer and other effectors contribute to ineffective and dysplastic MDS hemopoiesis. Despite the fact that several immunologic abnormalities have been described in MDS, the precise pathophysiologic mechanism underlying AIMs remains unclear. The encouraging biological insights into the autoimmune component of MDS pathophysiology can lead to the development of novel forms of treatment for controlling MDS process. MDS with AIMs constitute an ideal model in the investigation of disordered immune function in preleukemic states.Keywords
This publication has 45 references indexed in Scilit:
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changesBlood, 2009
- Myelodysplasia‐associated autoimmunity: clinical and pathophysiologic conceptsEuropean Journal of Clinical Investigation, 2004
- Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective studyRheumatology, 2004
- A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndromeBlood, 2003
- Antithymocyte Globulin for Treatment of the Bone Marrow Failure Associated with Myelodysplastic SyndromesAnnals of Internal Medicine, 2002
- Myelodysplastic syndrome is not merely “preleukemia”Blood, 2002
- Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietinLeukemia Research, 1997
- Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cellsBlood, 1996
- Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapyBritish Journal of Haematology, 1995
- Immune abnormalities in myelodysplastic syndromes.Journal of Clinical Pathology, 1985